Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity
- 1 September 2014
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 176 (2) , 550-552
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 10 references indexed in Scilit:
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptorCardiovascular Diabetology, 2013
- The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in ratsInternational Journal of Cardiology, 2013
- Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic OpportunitiesCNS & Neurological Disorders - Drug Targets, 2013
- A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of LinagliptinImmunology, Endocrine & Metabolic Agents in Medicinal Chemistry, 2013
- The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse BrainDiabetes, 2013
- Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission TomographyDiabetes Care, 2012
- Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic ApproachesCurrent Pharmaceutical Biotechnology, 2012
- Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in DiabetesCurrent Pharmaceutical Design, 2011
- The Role of Incretins in Glucose Homeostasis and Diabetes TreatmentPharmacological Reviews, 2008
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2008